Iovance Biotherapeutics Inc
A California biotech that turns a patient's own tumor-fighting immune cells into a cancer treatment, sold as the drug Amtagvi for advanced melanoma. It started in 2007 as Genesis Biopharma, later merged with Lion Biotechnologies, and took the name Iovance in 2017. Its Amtagvi became the first cell therapy the FDA approved for a solid tumor cancer in 2024.
Granted 13.35M
Bought 22.22M
Granted 13.35M
Bought 10.0K · Sold 100.0K
Granted 3.00M
Sold 2.78M
Granted 1.22M · Bought 125.0K
Bought 1.00M
Granted 40.0K · Bought 320.0K
Granted 921.9K · Bought 27.0K
Granted 13.35M · Bought 60.0K
Granted 550.0K
Granted 152.8K · Bought 5.6K
Granted 40.0K
Granted 180.0K
Granted 170.0K · Bought 30.0K
Granted 285.0K
Granted 278.7K
Sold 133.5K
Bought 10.0K
Granted 160.0K · Sold 169.0K
Granted 100.0K
Granted 128.5K
Granted 50.0K · Bought 7.5K · Sold 50.0K
Bought 54.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ayer Capital Management, LPDirector, 10% owner · 1 transaction | — | 560.40Mas of May 2013 | — | — | — |
| Kessler PaulChair,CEO, Pres., Pr.Acctg, Director · 1 transaction | — | 415.57Mas of Jul 2013 | 13.35M | — | — |
| Rothbaum Wayne P.Director · 7 transactions | — | 28.07Mas of Feb 2024 | — | 22.22M | — |
| Hamilton Atlantic10% owner · 4 transactions | — | 20.96Mas of Nov 2010 | — | — | — |
| Voyticky David JDirector · 3 transactions | — | 18.98Mas of Jul 2013 | 13.35M | — | — |
| Brooke Robert T.Former director and officer · 3 transactions | — | 4.44Mas of Mar 2011 | — | — | — |
| Bristol Investment Fund LTD10% owner · 3 transactions | — | 3.87Mas of Nov 2014 | — | 10.0K | 100.0K |
| Cataldo TonyCEO, President, Director · 1 transaction | — | 3.00Mas of May 2011 | 3.00M | — | — |
| ACM Capital Partners, LLC +2 co-filers10% owner · 1 transaction | — | 2.82Mas of May 2015 | — | — | 2.78M |
| Singh ManishPresident and CEO, Director, 10% owner · 3 transactions | — | 2.55Mas of Dec 2013 | 1.22M | 125.0K | — |
| McKilligan RichardFormer director and officer · 1 transaction | — | 1.22Mas of Mar 2011 | — | — | — |
| Schroeder MartinDirector · 1 transaction | — | 1.00Mas of Aug 2011 | — | 1.00M | — |
| McPeak Merrill ADirector · 10 transactions | — | 568.8Kas of Feb 2024 | 40.0K | 320.0K | — |
| Vogt Frederick GInterim CEO & General Counsel, Director · 49 transactions | — | 562.5K | 921.9K | 27.0K | — |
| McPeak Merrill A/Director · 4 transactions | — | 396.4Kas of Nov 2013 | 13.35M | 60.0K | — |
| Venkatesan Jay +3 co-filers10% owner, Director, 10% owner · 1 transaction | — | 312.5Kas of Jul 2014 | — | — | — |
| Fardis MariaPresident and CEO, Director · 39 transactions | — | 298.8Kas of Jun 2020 | 550.0K | — | — |
| Puri Raj K.Chief Regulatory Officer · 21 transactions | — | 248.1K | 152.8K | 5.6K | — |
| Hawkins ElmaPresident and CEO, Director · 2 transactions | — | 223.6Kas of Dec 2015 | 40.0K | — | — |
| Radvanyi LaszloChief Scientific Officer · 1 transaction | — | 180.0Kas of Jun 2014 | 180.0K | — | — |
| Kirby Daniel GordonChief Commercial Officer · 7 transactions | — | 146.9K | 170.0K | 30.0K | — |
| Graf Finckenstein FriedrichChief Medical Officer · 50 transactions | — | 144.1K | 285.0K | — | — |
| Bilinsky IgorChief Operating Officer · 50 transactions | — | 137.9K | 278.7K | — | — |
| Bristol Capital LLC10% owner · 5 transactions | — | 133.5Kas of Mar 2014 | — | — | 133.5K |
| Weiser MichaelDirector · 2 transactions | — | 133.3Kas of Jun 2022 | — | 10.0K | — |
| Hillsberg SanfordDirector · 10 transactions | — | 100.0Kas of Aug 2016 | 160.0K | — | 169.0K |
| Bender James G.Vice President, Manufacturing · 2 transactions | — | 88.7Kas of Sep 2015 | 100.0K | — | — |
| Bellemin Jean-MarcChief Financial Officer · 10 transactions | — | 65.0Kas of Jun 2025 | 128.5K | — | — |
| Maynard Ryan DDirector · 3 transactions | — | 57.5Kas of Nov 2024 | 50.0K | 7.5K | 50.0K |
| Dukes Iain D.Director · 3 transactions | — | 54.0Kas of Feb 2024 | — | 54.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +20.64M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.